Do analysts prefer IBRX or GMTX?

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 44.90%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts clearly believe ImmunityBio is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend PCVX or GMTX?

Vaxcyte presently has a consensus target price of $110.50, indicating a potential upside of 65.42%. Given Vaxcyte's stronger consensus rating and higher probable upside, research analysts plainly believe Vaxcyte is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, PCVX or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$7.63 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is PCVX or GMTX more profitable?

Vaxcyte's return on equity of -37.56% beat Gemini Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Gemini Therapeutics N/A -38.78% -35.88%

Do analysts rate GMTX or KRYS?

Krystal Biotech has a consensus target price of $377.20, indicating a potential upside of 17.45%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Krystal Biotech 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00

Do analysts rate GMTX or PTGX?

Protagonist Therapeutics has a consensus price target of $154.44, indicating a potential upside of 11.52%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 2.94

Do analysts prefer KYMR or GMTX?

Kymera Therapeutics presently has a consensus target price of $134.68, indicating a potential upside of 26.25%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kymera Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 1 Sell rating(s) 2 Hold rating(s) 23 Buy rating(s) 1 Strong Buy rating(s) 2.89 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Gemini Therapeutics (GMTX) Competitors

$60.48 -1.58 (-2.55%)

As of 10/12/2026

Compare

GMTX vs. IBRX, PCVX, KRYS, PTGX, and KYMR

Should you buy Gemini Therapeutics stock or one of its competitors? Gemini Therapeutics's main competitors and comparable companies include ImmunityBio (IBRX), Vaxcyte (PCVX), Krystal Biotech (KRYS), Protagonist Therapeutics (PTGX), and Kymera Therapeutics (KYMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gemini Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

ImmunityBio has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Gemini Therapeutics has lower revenue, but higher earnings than ImmunityBio. Gemini Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	91.68	-$351.40M	-$0.97	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

In the previous week, ImmunityBio had 9 more articles in the media than Gemini Therapeutics. MarketBeat recorded 9 mentions for ImmunityBio and 0 mentions for Gemini Therapeutics. ImmunityBio's average media sentiment score of 0.43 beat Gemini Therapeutics' score of 0.00 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Overall Sentiment
ImmunityBio	Neutral
Gemini Therapeutics	Neutral

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 44.90%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts clearly believe ImmunityBio is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Gemini Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Summary

ImmunityBio beats Gemini Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Vaxcyte presently has a consensus target price of $110.50, indicating a potential upside of 65.42%. Given Vaxcyte's stronger consensus rating and higher probable upside, research analysts plainly believe Vaxcyte is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Vaxcyte's return on equity of -37.56% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Vaxcyte has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Vaxcyte had 20 more articles in the media than Gemini Therapeutics. MarketBeat recorded 20 mentions for Vaxcyte and 0 mentions for Gemini Therapeutics. Vaxcyte's average media sentiment score of 0.36 beat Gemini Therapeutics' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Overall Sentiment
Vaxcyte	Neutral
Gemini Therapeutics	Neutral

Summary

Vaxcyte beats Gemini Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Gemini Therapeutics compare to Krystal Biotech?

Gemini Therapeutics (NASDAQ:GMTX) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Krystal Biotech has a net margin of 54.82% compared to Gemini Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Krystal Biotech	54.82%	19.34%	17.65%

In the previous week, Krystal Biotech had 10 more articles in the media than Gemini Therapeutics. MarketBeat recorded 10 mentions for Krystal Biotech and 0 mentions for Gemini Therapeutics. Krystal Biotech's average media sentiment score of 0.70 beat Gemini Therapeutics' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Krystal Biotech	Positive

Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Krystal Biotech has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Krystal Biotech	$389.13M	24.43	$204.83M	$7.98	40.25

Krystal Biotech has a consensus target price of $377.20, indicating a potential upside of 17.45%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Krystal Biotech beats Gemini Therapeutics on 16 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Protagonist Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Protagonist Therapeutics has a net margin of 29.40% compared to Gemini Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Protagonist Therapeutics has a consensus price target of $154.44, indicating a potential upside of 11.52%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Protagonist Therapeutics	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.94

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Protagonist Therapeutics had 11 more articles in the media than Gemini Therapeutics. MarketBeat recorded 11 mentions for Protagonist Therapeutics and 0 mentions for Gemini Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.14 beat Gemini Therapeutics' score of 0.00 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Protagonist Therapeutics	Neutral

Gemini Therapeutics has higher earnings, but lower revenue than Protagonist Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Protagonist Therapeutics	$46.02M	194.73	-$130.15M	$1.03	134.46

Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Gemini Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Gemini Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Gemini Therapeutics (NASDAQ:GMTX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

In the previous week, Kymera Therapeutics had 7 more articles in the media than Gemini Therapeutics. MarketBeat recorded 7 mentions for Kymera Therapeutics and 0 mentions for Gemini Therapeutics. Kymera Therapeutics' average media sentiment score of 0.61 beat Gemini Therapeutics' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kymera Therapeutics	Positive
Gemini Therapeutics	Neutral

Gemini Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Gemini Therapeutics	N/A	-38.78%	-35.88%

75.4% of Gemini Therapeutics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kymera Therapeutics presently has a consensus target price of $134.68, indicating a potential upside of 26.25%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kymera Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.89
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gemini Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	226.23	-$311.35M	-$3.24	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Kymera Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Summary

Kymera Therapeutics beats Gemini Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Gemini Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMTX vs. The Competition

Export

Metric	Gemini Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.62B	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-60.48	10.43	199.17	19.37
Price / Sales	N/A	1,157.81	564.77	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	20.93	16.93	10.70	6.03
Net Income	-$71.87M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-1.90%	-4.41%	-2.89%	-2.32%
1 Month Performance	-13.67%	-12.46%	-7.36%	-5.29%
1 Year Performance	-15.95%	7.64%	3.00%	-2.94%

Gemini Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMTX Gemini Therapeutics	N/A	$60.48 -2.5%	N/A	-13.5%	$2.62B	N/A	N/A	30	High Trading Volume
IBRX ImmunityBio	2.9636 of 5 stars	$9.75 +0.6%	$14.20 +45.6%	+295.2%	$10.27B	$113.29M	N/A	691
PCVX Vaxcyte	2.8057 of 5 stars	$66.96 +0.4%	$108.60 +62.2%	+52.5%	$9.93B	N/A	N/A	507	Analyst Forecast Gap Up High Trading Volume
KRYS Krystal Biotech	3.7029 of 5 stars	$324.57 -0.7%	$377.20 +16.2%	+73.8%	$9.67B	$389.13M	40.67	295
PTGX Protagonist Therapeutics	1.8339 of 5 stars	$140.92 +1.6%	$147.13 +4.4%	+74.9%	$8.97B	$46.02M	136.82	141	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMTX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gemini Therapeutics (GMTX) Competitors

GMTX vs. IBRX, PCVX, KRYS, PTGX, and KYMR

How does Gemini Therapeutics compare to ImmunityBio?

Summary

How does Gemini Therapeutics compare to Vaxcyte?

Summary

How does Gemini Therapeutics compare to Krystal Biotech?

Summary

How does Gemini Therapeutics compare to Protagonist Therapeutics?

Summary

How does Gemini Therapeutics compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gemini Therapeutics (GMTX) Competitors

GMTX vs. IBRX, PCVX, KRYS, PTGX, and KYMR

How does Gemini Therapeutics compare to ImmunityBio?

Which has more risk & volatility, IBRX or GMTX?

Which has higher earnings and valuation, IBRX or GMTX?

Does the media refer more to IBRX or GMTX?

Do analysts prefer IBRX or GMTX?

Do institutionals & insiders hold more shares of IBRX or GMTX?

Is IBRX or GMTX more profitable?

Summary

How does Gemini Therapeutics compare to Vaxcyte?

Do analysts recommend PCVX or GMTX?

Which has higher earnings and valuation, PCVX or GMTX?

Is PCVX or GMTX more profitable?

Which has more volatility and risk, PCVX or GMTX?

Do insiders & institutionals have more ownership in PCVX or GMTX?

Does the media refer more to PCVX or GMTX?

Summary

How does Gemini Therapeutics compare to Krystal Biotech?

Do insiders and institutionals have more ownership in GMTX or KRYS?

Is GMTX or KRYS more profitable?

Does the media favor GMTX or KRYS?

Which has more risk and volatility, GMTX or KRYS?

Which has higher valuation & earnings, GMTX or KRYS?

Do analysts rate GMTX or KRYS?

Summary

How does Gemini Therapeutics compare to Protagonist Therapeutics?

Is GMTX or PTGX more profitable?

Do analysts rate GMTX or PTGX?

Do insiders & institutionals have more ownership in GMTX or PTGX?

Does the media favor GMTX or PTGX?

Which has preferable earnings and valuation, GMTX or PTGX?

Which has more risk & volatility, GMTX or PTGX?

Summary

How does Gemini Therapeutics compare to Kymera Therapeutics?

Does the media refer more to KYMR or GMTX?

Is KYMR or GMTX more profitable?

Do insiders & institutionals have more ownership in KYMR or GMTX?

Do analysts prefer KYMR or GMTX?

Which has stronger valuation & earnings, KYMR or GMTX?

Which has more volatility & risk, KYMR or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools